Related Experiment Video

Updated: Oct 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Mycophenolate mofetil in the treatment of childhood systemic polyarteritis nodosa

Dharmagat Bhattarai1, Aaqib Zaffar Banday2, Harshita Nori2

  • 1Pediatrics, Om Hospital and Research Centre, Kathmandu, Bagmati, Nepal dharmagat@yahoo.co.uk.

BMJ Case Reports
|February 10, 2022
PubMed

Insights

Childhood systemic polyarteritis nodosa (PAN) can present with subtle signs, posing diagnostic challenges. Mycophenolate mofetil shows promise as an effective treatment for pediatric PAN, potentially reducing relapses.

Area of Science:

  • Pediatric Rheumatology
  • Systemic Vasculitis

Background:

  • Polyarteritis nodosa (PAN) is a medium vessel vasculitis characterized by necrotizing vascular changes and multisystemic involvement.
  • Diagnosing systemic PAN in children is complex due to variable presentations and requires thorough investigation.
  • Aggressive therapeutic strategies are essential for managing systemic PAN.

Observation:

  • A case of childhood systemic PAN is presented, initially manifesting with subtle signs including reduced sensation in the foot, non-deforming arthritis, and multiform rashes.
  • The diagnosis was confirmed through comprehensive etiological workup, nerve biopsy, and supporting evidence.
  • This case underscores the diagnostic challenges posed by vasculitis in children presenting with seemingly benign, non-specific symptoms.

Findings:

  • Mycophenolate mofetil is an emerging alternative treatment for PAN.
  • Evidence suggests successful treatment of PAN with mycophenolate mofetil, potentially leading to lower relapse rates.
  • This treatment may also increase treatment-free survival rates in patients with PAN.

Implications:

  • Clinicians should consider a broad differential diagnosis for non-specific multisystemic signs in children.
  • Lateral thinking is crucial for diagnosing challenging cases of pediatric vasculitis.
  • Mycophenolate mofetil represents a promising therapeutic option for childhood systemic PAN, warranting further investigation.
Keywords:
drugs: musculoskeletal and joint diseasesmusculoskeletal syndromesvasculitis

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.1K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
17
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
11
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
11
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
10
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
52